REVIEW

Circular RNAs: new biomarkers of chemoresistance in cancer

Jiaqi Wang¹,², Yi Zhang¹, Lianyu Liu¹,², Ting Yang¹, Jun Song¹,²
¹Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China; ²Institute of Digestive Diseases of Xuzhou Medical University, Xuzhou 221002, China

ABSTRACT
Chemotherapeutics are validated conventional treatments for patients with advanced cancer. However, with continual application of chemotherapeutics, chemoresistance, which is often predictive of poor prognosis, has gradually become a concern in recent years. Circular RNAs (circRNAs), a class of endogenous noncoding RNAs (ncRNAs) with a closed-loop structure, have been reported to be notable targets and markers for the prognosis, diagnosis, and treatment of many diseases, particularly cancer. Although dozens of studies have shown that circRNAs play major roles in drug-resistance activity in tumors, the mechanisms by which circRNAs affect chemoresistance have yet to be explored. In this review, we describe the detailed mechanisms of circRNAs and chemotherapeutics in various cancers and summarize potential therapeutic targets for drug-resistant tumors.

KEYWORDS
Circular RNA; chemoresistance; drug resistance; cancer

Introduction
Circular RNAs (circRNAs), which were first identified more than 4 decades ago¹, are a class of endogenous ncRNAs that have a closed-loop structure, and lack 5’ caps and 3’ poly (A) tails². Owing to their unique structure, circRNAs are more stable and less easily degraded than mRNAs³. Although circRNAs are abundant in eukaryotes, scientists initially considered them to have no meaningful function⁴. However, the development of high-throughput deep RNA sequencing and the application of bioinformatics technology has resulted in the confirmation of circRNAs as important molecules that are abnormally expressed and associated with poor prognosis in a variety of diseases, such as cardiovascular diseases⁵, diabetes⁶, nervous system diseases⁷, immune system diseases⁸, and cancer⁹.

Chemotherapeutics, which have been validated as conventional treatments for patients with advanced cancer, have widespread application in clinical practice. However, the development of chemoresistance, along with the need for chemotherapy treatment, is often predictive of poor prognosis¹⁰. Although the literature regarding drug resistance is extensive, the mechanisms involved require further clarification. In this review, we describe the relationship between circRNAs and chemoresistance, and discuss the mechanisms through which circRNAs contribute to drug resistance in different cancers.

Biogenesis of circRNAs

According to several studies, circRNAs are derived from canonical splice sites, and their biogenesis is dependent on the canonical splicing machinery¹¹,¹². However, Liang et al.¹³ have indicated that, when pre-mRNA processing events are slowed down, nascent RNA can be directed to alternative pathways that facilitate backsplicing. The main concept of backsplicing is that looping of the intron sequences flanking the downstream splice-donor (SD) site and the upstream splice-acceptor (SA) site brings these sites close together. Formation of this circular structure is mediated by base pairing between inverted repeat elements located in the upstream and downstream introns, or by the dimerization of RNA-binding proteins (RBPs) that bind particular motifs of lateral introns¹⁴. During backsplicing, an upstream branch point attacks a downstream SD site, which subsequently attacks an upstream SA site and results in the formation of exonic circRNAs (EcircRNAs) (Figure 1A).
Exon–intron circRNAs (EIciRNAs) (Figure 1B). In addition, during exon skipping, lariat formation, in which alternative exons are spliced out of the final mRNA product and are eventually included in the excised lariat, contribute to circRNA formation when the lariat undergoes internal backsplicing. Finally, intronic lariats that escape from debranching can lead to the formation of intronic circRNAs (Figure 1C).

Biological functions of circRNAs in cancer

Functions as miRNA sponges

MicroRNAs (miRNAs) are ncRNAs that negatively regulate mRNA translation through specific binding to target sites in the 3′ untranslated regions of mRNA. Many reported circRNAs contain miRNA response elements, which may play roles as miRNA sponges and serve as competing endogenous RNAs, thus preventing downstream target mRNAs from undergoing miRNA repression. Generally, according to most reports, one circRNA sponges a single miRNA sequence and plays a regulatory role. For example, CDR1as, which is known as a “super-sponge,” strongly sponges miR-7, which contains more than 70 selectively conserved binding sites, thereby affecting the occurrence and development of melanoma, non-small cell lung cancer, and other cancers. However, some circRNAs that act as RNA sponges, such as circHIPK3 and circCCDC66, can interact and regulate multiple miRNAs simultaneously. CircHIPK3, which is derived from exon 2 of the HIPK3 gene and consists solely of a large single exon (1,099 bp), may sponge as many as 9 miRNAs, as detected by luciferase reporter assays. In addition, circCCDC66 has been reported to sponge 4 different miRNAs in various cancers (Figure 2A).

Functions through RNA-binding proteins

Some circRNAs, similarly to their roles as miRNA sponges, bind RBPs, which play a crucial role in posttranscriptional modification and mRNA translation, and act as protein...
sponges affecting the expression of associated genes. A recent report has revealed that circZKSCAN1 competitively binds the RBP fragile X mental retardation protein (FMRP), thus preventing its binding to β-catenin-binding protein-cell cycle and apoptosis regulator 1 (CCAR1) mRNA and consequently leading to downregulation of the transcriptional activity of Wnt signaling targets in hepatocellular carcinoma (Figure 2B).

**Functions as transcriptional regulators**

CircRNAs regulate transcription through 2 recognized mechanisms. In one mechanism, circRNAs, particularly EIciRNAs (which are backspliced and retain introns), bind the polymerase II complex and interact with both the U1 small nuclear ribonucleoprotein (snRNP) complex and the promoters of their encoding genes. Two examples of this subgroup of circRNAs...
are ElciEIF3J and ElciPAIP2. If the interactions between these ElciRNAs and RNA polymerase II or U1 snRNPs are blocked, the mRNA transcription of their parental genes, eukaryotic translation initiation factor 3 subunit J (EIF3J) and poly (A)-binding protein-interacting protein 2 (PAIP2), respectively, is downregulated. Furthermore, the circRNA FECR1, which is derived from backsplicing between exon 4 and exon 2 of FLI1, activates FLI1 expression by interacting with the FLI1 promoter and subsequently induces extensive demethylation of CpG islands. Moreover, circFECR1 binds the promoters of DNMT1 and TET1, and regulates the expression of genes associated with DNA methylation and demethylation.

The other mechanism through which circRNAs (particularly EcircRNAs) regulate transcription is selective splicing. Because some circRNAs have functional binding sites, they can compete with linear mRNAs for canonical splicing and then alter the expression of their parental genes; for instance, circMbl interacts with the splicing complex, such that Mbl promotes the expression of circMbl. A pioneering study on titin, which was published just before the rediscovery of circRNAs, has shown that a subset of circRNAs that originate from the I-band of the titin gene are regulated by the splicing factor RBM20. These results demonstrate another aspect of the relationship between circRNAs and selective splicing.

**Functions in protein translation**

CircRNAs were previously considered to lack the ability to be translated, because they do not possess 5’ cap structures, poly (A) tails, or internal ribosome entry sites, all of which are essential for translation. However, more recent studies have debunked this theory. An open reading frame in circZNF609 has been reported to be recognizable by a splicing-dependent and cap-independent mechanism. The translation mechanism driven by N6-methyladenosine (m6A) modification has become another area of interest. YTHDC1, an m6A reader, has been found to recognize modifications on circNSUN2 and then facilitate circNSUN2 export from the nucleus to the cytoplasm; this activity directly increases the invasion ability of colorectal cancer (CRC) (Figure 2D).

**Mechanisms of chemoresistance in circRNAs**

Chemotherapy plays an indispensable role in the treatment of cancer, particularly advanced cancer. However, chemoresistance emerges and then becomes an urgent obstacle to overcome. Many reports have described the mechanisms of drug resistance in cancer, which include (1) promoting drug excretion by expressing ATP-binding cassette (ABC) transporters such as ABCB1, ABCC1, and ABCG2, which are often overexpressed in drug-resistant cancer cells and result in lower drug accumulation in cells; (2) dysregulating the expression of anti-apoptotic genes (e.g., upregulating the expression of the antiapoptotic genes Bcl-2 and MDM2, or repressing the expression of tumor suppressors such as p53), thus allowing cancer cells to proliferate indefinitely without constraint; (3) enhancing the capacity for DNA repair (e.g., in CD133 positive glioma stem cells, which show increased activation of checkpoint-related proteins and other proteins involved in the DNA damage response); and (4) creating a tumor microenvironment (TME) with an altered proportion of stromal fibroblasts, vasculature, and immune cells (Figure 3). In addition to these mechanisms, many other factors, such as tumor heterogeneity, autophagy, and gene mutations, affect drug resistance.

Although dozens of studies have shown that circRNAs play major roles in drug-resistance activity in tumors, the mechanisms through which circRNAs affect chemoresistance have yet to be explored. In the next section, circRNAs and their mechanisms relating to drug resistance are summarized in detail.

**The roles of circRNAs in cancer chemoresistance**

The mechanisms through which circRNAs regulate the development of drug resistance in cancer are shown in Tables 1 and 2.

**CircRNAs affecting cell apoptosis in chemoresistance**

Apoptosis is programmed cell death, which is regulated at the genetic level and removes damaged cells in an orderly and efficient manner. The elimination of this death process is associated with unchecked cell proliferation, cancer development and progression, and cancer resistance to chemotherapies. Consequently, dysregulation of molecules involved in apoptotic resistance often leads to treatment failure. According to extensive research, dozens of circRNAs downregulate apoptosis in cancer cells by regulating apoptosis-related genes.
thereby leading to drug resistance. In the next paragraph, we briefly introduce the circRNAs that dysregulate apoptosis-related genes in cancers.

In breast cancer (BC), dysregulation of circKDM4C and hsa_circ_0006528 is associated with doxorubicin resistance. CircKDM4C, which is downregulated in BC, mitigates doxorubicin resistance by sponging miR-548p and targeting PBLD, a tumor suppressor in BC. Additionally, hsa_circ_0006528, which is upregulated in doxorubicin-resistant cell lines, functions as an miRNA sponge via the miR-7-5p/Raf1 axis and contributes to doxorubicin resistance. CDR1as is thought to promote 5-FU resistance in BC by competitively inhibiting miR-7 and consequently regulating CCNE1 expression. CircRNF111 and circABCB10, both of which sponge miRNAs, induce paclitaxel resistance. In cervical cancer, hsa_circ_0023404 and circMTO1 both enhance the resistance to cisplatin and function as miRNA sponges that regulate beclin1 and p62. In CRC, hsa_circ_0007031 and hsa_circ_0000504 promote 5-FU resistance by sponging miR-885-3p and miR-485-5p, and ultimately upregulate AKT3 and BCL2 expression. Moreover, hsa_circ_0048234 represses 5-FU resistance via the miR-671-5p/EGFR axis. In addition, circPRKDC enhances resistance to 5-FU via the miR-375/FOXM1/Wnt/β-catenin pathway. A recent study has revealed that circCCDC66 promotes oxaliplatin resistance in CRC by interacting with a set of miRNAs and consequently regulating the expression of multiple genes that facilitate cell apoptosis and survival. In addition, oxaliplatin induces circCCDC66 expression by
| Cancer         | circRNAs           | Role    | Mechanism     | Target/pathway                  | Drug     | Ref |
|---------------|-------------------|---------|---------------|---------------------------------|----------|-----|
| BC            | circKDM4C         | Down    | miRNA sponge  | miR-548p/PBLD                   | Doxorubicin | 39  |
|               | hsa_circ_0006528  | Up      | miRNA sponge  | miR-7-5p/Raf1                   | Doxorubicin | 40  |
|               | CDR1as            | Up      | miRNA sponge  | miR-7/CCNE1                     | S-FU     | 41  |
|               | circRNF111        | Up      | miRNA sponge  | miR-140-5p/E2F3                 | Paclitaxel| 42  |
|               | circABCB10        | Up      | miRNA sponge  | let-7a-5p/DUSP7                 | Paclitaxel| 43  |
| Cervical cancer | hsa_circ_0023404  | Up      | miRNA sponge  | miR-5047/BCL1/p62               | Cisplatin | 44  |
|               | circMTO1          | Up      | miRNA sponge  | miR-6893/BCL1/p62               | Cisplatin | 45  |
| CRC           | hsa_circ_0007031  | Up      | miRNA sponge  | miR-885-3p/AKT3/BCL2            | S-FU     | 46  |
|               | hsa_circ_0000504  | Up      | miRNA sponge  | miR-485-5p/AKT3/BCL2            | S-FU     | 47  |
|               | hsa_circ_0048234  | Down    | miRNA sponge  | miR-375/FOX11/MI/β-catenin      | S-FU     | 48  |
| CRC           | circPRKDC         | Up      | miRNA sponge  | –                               | Oxaliplatin| 49  |
|               | circCCDC66        | Up      | miRNA sponge  | –                               | –        | 50  |
| GC            | circPVT1          | Up      | miRNA sponge  | miR-30a-5p/YAP1                 | Cisplatin | 51  |
|               | circFN1           | Up      | miRNA sponge  | miR-182-5p/caspase-3            | Cisplatin | 52  |
|               | hsa_circ_0000520  | Down    | miRNA sponge  | PI3K/AKT                        | Herceptin | 53  |
| Glioma        | circHIPK3         | Up      | miRNA sponge  | miR-421/ZIC5                    | TMZ      | 54  |
|               |                   |         |               | miR-524-5p/KIF2A/PI3K/AKT       |          |     |
| HCC           | hsa_circ_0003418  | Down    | miRNA sponge  | miR-7/miR-383/Wnt/β-catenin     | Cisplatin | 55  |
|               | hsa_circ_101505   | Down    | miRNA sponge  | miR-103/NOR1                    | Cisplatin | 56  |
| Lung cancer   | hsa_circ_0085131  | Up      | miRNA sponge  | miR-654-5p/ATG7                 | Cisplatin | 57  |
|               | hsa_circ_0076305  | Up      | miRNA sponge  | miR-296-5p/STAT3                | Cisplatin | 58  |
|               | hsa_circ_0007385  | Up      | miRNA sponge  | miR-519-3p/HMGB1                | Cisplatin | 59  |
|               | hsa_circ_0004350  | Up      | RBP sponge    | EIF3a                          | Cisplatin | 60  |
|               | hsa_circ_0092857  | Up      | RBP sponge    | EIF3a                          | Cisplatin | 61  |
|               | hsa_circ_0096157  | Up      | –             | p21/CCND1/CDK4/BCL2             | Cisplatin | 62  |
|               | CDR1as            | Up      | –             | EGFR/PI3K                       |          |     |
|               |                   |         |               |                                 | Paclitaxel| 63  |
|               | hsa_circ_0002483  | Down    | miRNA sponge  | miR-182-5p/GRB2/FOXO1/FOXO3     | Paclitaxel| 64  |
|               | hsa_circ_0011292  | Up      | miRNA sponge  | miR-379-5p/TRIM65               | Paclitaxel| 65  |
|               | hsa_circ_0004015  | Up      | miRNA sponge  | miR-1183/PDPK1                  | Gefitinib | 66  |
|               | hsa_circ_0003998  | Up      | miRNA sponge  | miR-326                         | Docetaxel | 67  |
|               | hsa_circ_0002130  | Up      | miRNA sponge  | miR-498                         | Osimertinib| 68  |
| OS            | hsa_circ_0001258  | Down    | miRNA sponge  | miR-744-3p/GSTM2                | Doxorubicin| 69  |
|               |                   |         |               |                                 | Cisplatin | 70  |
|               |                   |         |               |                                 | Methotrexate| 71  |
phosphorylating DHX9, which is involved in multiple pathways associated with the DNA damage response. In gastric cancer (GC), circPVT1 and circFN1 are significantly upregulated in paclitaxel-resistant GC tissues and cells, and these circRNAs have been predicted to regulate apoptosis via an miRNA sponge mechanism. Sun et al. have found that hsa_circ_0000520 enhances the sensitivity of herceptin in GC cells by targeting at PI3K/AKT. In glioma, circHIPK3 has been found to enhance cell proliferation and temozolomide (TMZ) resistance, not only by sponging miR-421/ZIC5 but also via the miR-524-5p/KIF2A/PI3K/AKT axis. In hepato-cellar carcinoma (HCC), both hsa_circ_0003418 and hsa_circ_00150560 enhance cell apoptosis and the sensitivity to cisplatin through an miRNA sponge mechanism. In lung cancer, 3 circRNAs leading to cisplatin resistance by sponging miRNAs have been identified: hsa_circ_0076305, hsa_circ_0007385, and hsa_circ_0085131. Moreover, hsa_circ_0004350 and hsa_circ_0092857, both of which decrease cells' sensitivity to cisplatin, can interact with RBPs and may have a synergistic effect with the parental EIF3a gene. In ovarian cancer, the overexpression of circCELSR1 and circTNPO3 results in paclitaxel resistance by repressing cell apoptosis and regulating the cell cycle. In prostate cancer (PCa), Gao et al. have discovered that hsa_circ_0000735 overexpressed in PCa tissue, and downregulated of hsa_circ_0000735 boosts docetaxel sensitivity by promoting cell apoptosis. Hsa_circ_0000735 contributes to gemcitabine-induced autophagy and facilitates resistance of renal cell carcinoma (RCC) to gemcitabine via the EGFR/Pi3K signaling pathway. Other circRNAs functioning as miRNA sponges in lung cancer include hsa_circ_0002483 and hsa_circ_0011292 against paclitaxel, hsa_circ_0004015 against gefitinib, and hsa_circ_0003998 against docetaxel, and hsa_circ_0002130 against osimertinib. In osteosarcoma (OS), hsa_circ_0001258 has been found to decrease the resistance to doxorubicin, cisplatin, and methotrexate via miR-744-3p/GSTM2. Furthermore, hsa_circ_0004674 and hsa_circ_0000073 repress cell apoptosis and resist methotrexate by sponging miRNAs, and hsa_circ_001569 represses cisplatin sensitivity via Wnt/β-catenin. In ovarian cancer, CDR1as, in contrast to its role in BC and lung adenocarcinoma, is downregulated in cisplatin-resistant ovarian cancer tissues, and it decreases the resistance of cells to cisplatin via the miR-1270/SCAI axis.

| Cancer            | circRNAs          | Role   | Mechanism          | Target/pathway      | Drug          | Ref |
|-------------------|-------------------|--------|--------------------|---------------------|---------------|-----|
| hsa_circ_0004674  | Up                | miRNA sponge | miR-1254/EGFR     | Methotrexate        | 68  |
| hsa_circ_0000073  | Up                | miRNA sponge | miR-145-5p/miR-151-3p/NRAS | Methotrexate        | 69  |
| hsa_circ_0015669  | Up                | –      | Wnt/β-catenin      | Cisplatin           | 70  |
| Ovarian cancer    | circCELSR1        | Up     | miRNA sponge       | miR-1252/FOX2R2     | Paclitaxel    | 71  |
|                   | circTNPO3         | Up     | miRNA sponge       | miR-1299/NEK2       | Paclitaxel    | 72  |
|                   | CDR1as            | Down   | miRNA sponge       | miR-1270/SCAI       | Cisplatin     | 73  |
| PCa               | hsa_circ_0000735  | Up     | miRNA sponge       | miR-7                | Docetaxel     | 74  |
| RCC               | hsa_circ_0035483  | Up     | miRNA sponge       | miR-335/CCNB1       | Gemcitabine   | 75  |
| Thyroid carcinoma | circEIF6          | Up     | miRNA sponge       | miR-144-3p/TGF-α    | Cisplatin     | 76  |
| CML               | hsa_circ_009910   | Up     | miRNA sponge       | miR-34a-5p/ULK1     | Imatinib      | 77  |
|                   | hsa_circ_0080415  | Up     | miRNA sponge       | miR-326/PPFIA1      | Imatinib      | 78  |
|                   | circBA9.3         | Up     | –                  | c-ABL1/BCR-ABL1     | TKIs          | 79  |
| AML               | circPAN3          | Up     | miRNA sponge       | AMPK/mTOR           | Doxorubicin   | 80  |
|                   |                   |        |                    |                     | miR-183-5p/XIAP|     |
resistance via miR-144-3p/TGF-α in thyroid carcinoma. In chronic myeloid leukemia (CML), hsa_circ_0009910 and hsa_circ_0080145 repress cell apoptosis and sensitivity to imatinib by acting as miRNA sponges. CircBA9.3, which promotes proliferation and inhibits apoptosis in cancer cells, enhances resistance to tyrosine kinase inhibitors (TKIs) by increasing the expression of the c-ABL1 and BCR-ABL1 oncoproteins, which contribute to the immortality of leukemic cells. CircPAN3, a circRNA highly expressed in doxorubicin-resistant acute myeloid leukemia (AML) cells, functions
as an miRNA sponge that regulates autophagy and influences the expression of apoptosis-related proteins via the AMPK/mTOR signaling pathway, and ultimately contributes to doxorubicin resistance85. In general, circRNAs reverse drug sensitivity by regulating the expression of apoptosis-associated genes, thus repressing cancer cell death.

**CircRNAs promoting drug excretion in chemoresistance**

The ABC transporter family comprises 48 genes subdivided into 7 subfamilies: ABCA through ABCG86. Most these genes encode large membrane proteins that function in the energy dependent transport of xenobiotics, metabolites, and signaling molecules across cell membranes, often against their concentration gradients87. Two ATP-binding sites in ABC transporters have been reported to participate in the formation of the ATP binding pocket, and their interactions are essential for coupling ATP hydrolysis to drug transport and ultimately cause chemoresistance88. According to recent studies, a group of circRNAs can target at ABC transporters and then promote drug excretion, thereby inducing drug resistance.

On the one hand, some circRNAs indirectly enhance the functionality of ABC transporters. Hsa_circ_0005963 has been found to promote oxaliplatin resistance via the miR-122/PKM2 axis89, thus enhancing glycolysis and ATP production and facilitating oxaliplatin excretion by ABC transporters in CRC. On the other hand, circRNAs can upregulate the ABC transporter family directly. Overexpression of hsa_circ_0004674 confers resistance to doxorubicin and cisplatin via the miR-490-3p/ABCC2 axis in OS73. CircPVT1 not only facilitates resistance to cisplatin and doxorubicin by enhancing the expression of ABCB1 in OS90, but also functions through miR-145-5p/ABCC1 in lung cancer, thus resulting in resistance to cisplatin and pemetrexed91. Hsa_circ_0109291, like circPVT1, targets ABCB1 by sponging miR-188-3p and consequently rendering cisplatin ineffective in oral squamous cell carcinoma (OSCC)92. He et al.93 have found that hsa_circ_0007031 represses 5-FU sensitivity via the miR-133b/ABCC5 axis in CRC. Xu et al.94 have demonstrated that circMTHFD2 significantly promotes the expression of ABCG2 and resistance to TMZ by sponging miR-145-5p in glioma. In addition, in multiple myeloma (MM), overexpression of hsa_circ_0007841 leads to high levels of ABCG2 and consequently decreases doxorubicin’s efficacy95. These results suggest that circRNAs can directly or indirectly regulate the expression of ABC transporters and eventually induce drug resistance by promoting drug excretion.

**CircRNAs promoting DNA repair in chemoresistance**

DNA repair is a biological event in which cells identify and correct DNA damage induced by chemotherapy and other incidents. The main mechanisms comprise base excision repair, nucleotide excision repair, mismatch repair, homologous recombination repair, nonhomologous end-joining, and interstrand crosslink repair, which can confer resistance to DNA-targeting chemotherapeutics97. Therefore, understanding the activity of different DNA repair pathways in individual tumors and the correlation between DNA repair function and drug response will be key in the selection of targeted drugs for patients. Because ncRNAs are a widespread concern, multiple circRNA-mediated DNA damage repair mechanisms leading to drug resistance have been discovered.

Eg5, a member of the kinesin family, whose members are crucial for maintaining separation of the half-spindles, is a microtubule-based motor protein required for the formation and maintenance of the bipolar spindle98,99. Monastrol, a reversible, cell-permeable small molecule, selectively inhibits Eg5 and consequently disrupts the structure of tumor cells’ chromosomes and DNA100. A recent study has identified a circular RNA, circMTO1, that is significantly downregulated in monastrol resistant cells and reverses monastrol resistance through RBP targeting at TRAF4/Eg5101.

Cisplatin, first synthesized by Michele Peyrone and approved by the US FDA for use in testicular and ovarian cancer in 1979102, binds DNA and forms adducts once inside tumor cells. The primary forms of DNA damage are N7-d (GpG) and N7-d (ApG) intrastrand DNA-platinum adducts, which cause substantial kinking of DNA103. In GC, both circAKT3 and hsa_circ_0026359 have been verified to induce cisplatin resistance. Huang et al.104 have identified that circAKT3 promotes DNA damage repair via the miR-198/PIK3R1. Hsa_circ_0026359 sponges miR-1200 and upregulates POLD4105, and low expression of hsa_circ_0026359 has been reported to weaken DNA repair systems106. In addition, circPRMT5 overexpression in lung cancer enhances cisplatin resistance by upregulating REV3L, which encodes the catalytic subunit of DNA polymerase ζ and is responsible for translesional replication107.
In summary, circRNAs activate related proteins or pathways, thus maintaining chromosome or DNA stability, and promote DNA damage repair, thereby leading to chemotherapy failure.

**CircRNAs influencing the TME in chemoresistance**

The TME, the cellular environment in which tumors exist, has been characterized as hypoxic, acidic, inflammatory, and immunosuppressive. Beyond tumor cells, the TME contains the extracellular matrix, surrounding blood vessels, and other non-malignant cells. The TME is considered a “sanctuary of the devil,” in that immune cells in the TME secrete cytokines, inflammatory factors, and chemokines and drive the epithelial to mesenchymal transition (EMT) process in cancer cells via various pathways. In turn, cancer cells interact with immune cells and induce cellular plasticity and the release of immunosuppressive substances; consequently an immunosuppressive microenvironment that promotes immune escape and drug resistance is created.

Several studies have shown that circRNAs alter the TME by regulating EMT and immune escape, and ultimately result in drug resistance. Hu et al. have reported that circUBE2D2 accelerates the progression of EMT and enhances resistance to tamoxifen in BC. CircPVT1, which is expressed at high levels in paclitaxel-resistant GC cells, sponges miR-124-3p and upregulates ZEB1, a crucial transcriptional inhibitor of E-cadherin that expedites EMT. CircMET overexpression promotes an HCC immunosuppressive tumor microenvironment by inducing EMT through the miR-30-5p/Snail/DPP4/CXCL10 axis and leads to anti-PD1 therapy resistance. In lung cancer, circFGFR1 has a critical role in immune evasion and induces resistance to anti-PD1 based therapy via the miR-381-3p/CXCR4 axis. In addition, circCCDC66 promotes EMT and represses cisplatin sensitivity in lung adenocarcinoma. Through this mechanism, circRNAs mainly alter the TME by regulating EMT, thus allowing cancer cells to escape drug and immune injury.

**CircRNAs regulating CSCs in chemoresistance**

CSCs are a group of self-renewing cells that have high tumorigenic capacity and play crucial roles in chemoresistance, accelerating tumor regrowth after therapy. CSCs share many characteristics with regenerative stem cells, such as self-renewal, multipotency, and the reversibility of their quiescent state. After chemotherapy, residual bodies enriched in CSCs remain, which can promote tumor recurrence, re-grow metastatic tumors, and enhance resistance to drugs.

To date, 3 circRNAs have been reported to influence CSC-like phenotypes. CircELP3, which is elevated in hypoxic environments, enhances cisplatin resistance in bladder cancer by displaying a high self-renewal capacity, as evidenced by high levels of sphere formation and stem cell marker expression. Similarly, both hsa_circ_001680, resisting irinotecan in CRC, and circCAP4, resisting cisplatin in lung cancer, strengthen stem cell-like traits, self-renewal and tumor-initiating capacity via increasing stemness associated signatures and sphere formation. In conclusion, circRNAs increase cancer cells’ stemness, thus protecting tumors against chemotherapeutics.

**CircRNAs mediating endocrine therapy in chemoresistance**

Endocrine therapy plays a unique role in the treatment of cancer, particularly in BC and PCa. The estrogen receptor, which is expressed in approximately 70% of all BC, is considered the main factor inducing BC. Tamoxifen, an anti-estrogen that decreases estrogen-induced effects by blocking the estrogen receptor in breast tissue, remains a cornerstone treatment that has significantly improved clinical outcomes. Simultaneously, as an effective therapeutic target in PCa, the androgen receptor, is expressed in nearly all PCa and results in an abnormal gene expression profile, including cell cycle regulators, transcription factors, and genes important for cell survival, lipogenesis, and secretion. Antiandrogenic drugs such as enzalutamide inhibit the progression of PCa by blocking androgens. However, the development of drug resistance is inevitable after the first chemotherapy, and some circRNAs have been reported to participate in the progression of endocrine-related resistance.

In BC, 2 circRNAs that are downregulated in BC cells have been found to act synergistically with tamoxifen. Sang et al. have demonstrated that overexpressed hsa_circ_0025202 sponges miR-182-5p and upregulates FOXO3a, an inhibitor of tamoxifen resistance in BC. CircBMPR2 acts as an miR-553 sponge, thereby preventing it from repressing the tumor suppressor USP4, and subsequently mitigates tamoxifen resistance. To date, downregulation of 3 circRNA in PCa cells has been reported to lead to increased resistance to enzalutamide. Low hsa_circ_0004870 expression results in the upregulation of its parental gene RBM39 and the downstream target gene...
AR-V7, whose expression is positively correlated with enzalutamide resistance. Another circRNA that targets AR-V7 is hsa_circ_0001427. Interestingly, hsa_circ_0001427 is positively correlated with miR-181c-5p, which directly binds and degrades the ARv7 3’ untranslated region and may stabilize miR-181c-5p, thus ultimately decreasing cells’ resistance to enzalutamide. Finally, CircUCK2, whose expression is downregulated in enzalutamide-resistant cells, may function as an miRNA sponge through the miR-767-5p/TET1 axis. These results suggest that circRNAs regulate the effects of endocrine drugs by changing relative receptor levels, thereby potentially providing new directions in hormone-dependent cancer therapy.

Discussion

Because of the vast amount of research on cancer, a variety of targeted chemotherapy drugs have been widely used in clinical settings and have achieved good efficacy. The most common mechanism of chemotherapy is inducing cancer cell death by damaging DNA to inhibit tumor growth. In contrast, the mechanisms of tumor drug resistance include promoting drug excretion and DNA repair, inhibiting apoptosis, and creating a TME resistant to the damage caused by chemotherapy drugs.

According to the literature, the multi-drug resistance of circRNAs may manifest different roles in different cancers. For example, CDR1as promotes resistance to cisplatin, 5-FU, and pemetrexed in BC and lung cancer, but it enhances the sensitivity of ovarian cancer to cisplatin. Although CDR1as appears to play a crucial role in the chemoresistance of cancers, whether an opposite effect might occur in different cancers, owing to the heterogeneity and origin of tumors, remains unknown. Moreover, reports on circRNA-related chemoresistance have largely focused on their mechanisms as miRNA sponges, which function via interactions between circRNA and miRNAs that regulate downstream genes and ultimately influence drug effects. In contrast, only few studies have reported the mechanisms of circRNAs as they relate to RBPs. Although circRNAs are known to regulate transcription and translation, these 2 mechanisms have not been reported in terms of circRNA-related drug resistance. Instead, dozens of studies have shown that ncRNAs influence chemoresistance by regulating transcription and translation; for example, miR-5787 affects the translation of mitochondrial cytochrome c oxidase subunit 3 (MT-CO3), thus regulating cisplatin resistance, and miR-182-5p, regulates GLI2, a transcriptional regulator of the hedgehog signaling pathway. Therefore, a knowledge gap regarding the mechanisms of circRNA-related drug resistance remains to be further explored.

Currently, RNA-seq, owing to its high throughput, accuracy, and sensitivity, is the gold standard for screening circRNAs associated with drug resistance. Most studies use RNA-seq to screen circRNAs with differential expression patterns between resistant and nonresistant cell lines, to explore mechanisms of chemoresistance. Interestingly, some studies have shown not only that circRNAs influence multi-drug resistance but also that drug feedback regulation on circRNAs exists. For example, circCCDC66 is a circRNA that is induced by treatment with oxaliplatin and subsequently promotes resistance to oxaliplatin-induced apoptosis. Future studies may reveal new mechanisms for the occurrence and enhancement of drug resistance. Blocking these mechanisms could substantially support the elimination of chemoresistance. This research direction is especially applicable to the clinical study of drug resistance and may provide new directions for the exploration of the mechanisms of circRNA-related chemoresistance.

With the recent development of liquid biopsy, examination of secretions, and other clinical techniques, circRNAs have broad application prospects as early screening indicators of drug sensitivity. For example, as mentioned above, hsa_circ_0025202 has an anti-oncogenic role in HR-positive breast cancer, and it may be exploited as a novel marker for tamoxifen-resistant breast cancer. Meanwhile, with research advances, many clinical trials are underway that are targeting ncRNAs, including a mimic of the tumor suppressor miRNA miR-34, which has reached phase I clinical trials. Because circRNAs are emerging research targets, relevant clinical studies remain lacking, although many reports have already shown that circRNAs are associated with cancer progression and drug resistance, possibly because of the high toxicity and low specificity of the inhibitors, which are difficult to put into clinical use. In general, how to accurately target circRNAs to tumor cells and minimize the damage to healthy cells is an urgent problem that must be solved.

Conclusions

In summary, circRNAs have been shown to be involved in tumor progression and to be closely associated with drug resistance. We summarized the mechanisms through which circRNAs interact with RBPs and miRNAs, and consequently
influence drug delivery, reverse drug-induced apoptosis, and ultimately lead to drug resistance. However, many unknown circRNAs and mechanisms of drug resistance remain to be discovered and elucidated. Therefore, in-depth exploration in this field may provide a broader space for further research and treatment of chemoresistance mechanisms in tumors. circRNAs may have extensive roles in the treatment of tumors in the future.

Grant support

This research was supported in part by the National Natural Science Foundation of China (Grant Nos. 81702435 and 82073133), the Natural Science Foundation of Jiangsu Province (Grant Nos. BK20170264 and BK20191154), and the Six Talent Peaks Project in Jiangsu Province (Grant No. WSW-050).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids
2. Auferio S, van den Hoogenhof MMG, Reckman YJ, Beqqali A, van der Made I, et al. Cardiac circRNAs arise mainly from constitutive exons rather than alternatively spliced exons. RNA. 2018; 24: 815-27.
3. Li D, Yang Y, Li ZQ, Li LC, Zhu XH. Circular RNAs: from biogenesis and function to diseases. Chin Med J. 2019; 132: 2457-64.
4. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993; 73: 1019-30.
5. Zhou S, Jiang H, Li M, Wu P, Sun L, Liu Y, et al. Circular RNA hsa_circ_0016070 is associated with pulmonary arterial hypertension by sponging multiple miRNAs. Nat Commun. 2016; 7: 11215.
6. Liu C, Ge HM, Liu BH, Dong R, Shan K, Chen X, et al. Targeting pericyte-endothelial cell crosstalk by circular RNA-cPWWP2A inhibition aggravates diabetes-induced microvascular dysfunction. Proc Natl Acad Sci U S A. 2019; 116: 7455-64.
7. Dube U, Del-Aguila Jl, Li Z, Bodde JP, Jiang S, Hsu S, et al. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Nat Neurosci. 2019; 22: 1903-12.
8. Chen X, Yang T, Wang W, Xi W, Zhang T, Li Q, et al. Circular RNAs in immune responses and immune diseases. Theranostics. 2019; 9: 588-607.
9. Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nat Commun. 2019; 10: 3200.
10. Zhao J. Cancer stem cells and chemoresistance: the smartest survives the raid. Pharmacol Ther. 2016; 160: 145-58.
11. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19: 141-57.
12. Starke S, Jost I, Rossbach O, Schneider T, Schreiner S, Hung LH, et al. Exon circularization requires canonical splice signals. Cell Rep. 2015; 10: 103-11.
13. Liang D, Tatomer DC, Luo Z, Wu H, Yang L, Chen LL, et al. The output of protein-coding genes shifts to circular RNAs when the Pre-mRNA processing machinery is limiting. Mol Cell. 2017; 68: 940-54.e3.
14. Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell. 2014; 159: 134-47.
15. Eger N, Schoppe L, Schuster S, Laufs U, Boeckel JN. Circular RNA splicing. Adv Exp Med Biol. 2018; 1087: 41-52.
16. Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013; 51: 792-806.
17. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev. 2011; 91: 827-87.
18. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res. 2013; 73: 5609-12.
19. Hanniford D, Ulloa-Morales A, Karz A, Berzoti-Coelho MG, Moubarak RS, Sanchez-Sendra B, et al. Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis. Cancer Cell. 2020; 37: 55-70.e15.
20. Su C, Han Y, Zhang H, Li Y, Yi L, Wang X, et al. CiRS-7 targeting miR-7 modulates the progression of non-small cell lung cancer in a manner dependent on NF-kappaB signalling. J Cell Mol Med. 2018; 22: 3097-107.
21. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016; 7: 11215.
22. Wang L, Peng X, Lu X, Wei Q, Chen M, Liu L. Inhibition of hsa_circ_0001313 (circCCDC66) induction enhances the radiosensitivity of colon cancer cells via tumor suppressor miR-338-3p: effects of cicr_0001313 on colon cancer radio-sensitivity. Pathol Res Pract. 2019; 215: 689-96.
23. Wang Y, Zhao W, Zhang S. STAT3-induced upregulation of circCCDC66 facilitates the progression of non-small cell lung cancer by targeting miR-33a-5p/KPNA4 axis. Bioimed Pharmacother. 2020; 126: 110019.
24. Zhang Q, Miao Y, Fu Q, Hu H, Chen H, Zeng A, et al. CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis. Biochem Biophys Res Commun. 2020; 526: 713-20.
25. Yang M, Wang G, Qian H, Ji X, Liu C, Zeng X, et al. Circ-CCDC66 accelerates proliferation and invasion of gastric cancer via binding to miRNA-1238-3p. Eur Rev Med Pharmacol Sci. 2019; 23: 4164-72.
26. Zhu YJ, Zheng B, Luo GJ, Ma XK, Lu XY, Lin XM, et al. Circular RNAs negatively regulate cancer stem cells by physically binding FMRP against CCA1 complex in hepatocellular carcinoma. Theranostics. 2019; 9: 3526-40.
27. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17: 205-11.
28. Li Z, Huang C, Bao C, Chen L, Lin M, Wang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Curr Issues Mol Biol. 2015; 22: 256-64.
29. Chen N, Zhao G, Yan X, Lv Z, Yin H, Zhang S, et al. A novel FLI1 exonic circular RNA promotes metastasis in breast cancer by coordinately regulating TET1 and DNMT1. Genome Biol. 2018; 19: 218.
30. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56: 55-66.
31. Khan M, Reckman Y, Auflero S, van den Hoogenhof M, van der Made I, Beqali A, et al. RBM20 regulates circular RNA production from the titin GENE. Circ Res. 2016; 119: 996-1003.
32. Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. Mol Cancer. 2017; 16: 58.
33. Legnini I, Di Timoteo G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. 2017; 66: 22-37.
34. Chen RX, Chen X, Xia LP, Zhang JX, Pan ZZ, Ma XD, et al. N-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis. Nat Commun. 2019; 10: 4695.
35. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018; 18: 452-64.
36. Johnston RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108: 153-64.
37. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-60.
38. Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013; 501: 346-54.
39. O’Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015; 21: 249-57.
40. Iacobuzio-Donahue CA, Michael C, Baez P, Kappagantula R, Hooper JE, Hollman TJ. Cancer biology as revealed by the research autopsy. Nat Rev Cancer. 2019; 19: 686-97.
41. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Teijpar S, KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011; 12: 594-603.
42. Fuchs Y, Steller H. Programmed cell death in animal development and disease. Cell. 2011; 147: 742-58.
43. Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem. 2008; 104: 1124-49.
44. Liang Y, Song X, Li Y, Su P, Han D, Ma T, et al. circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 2019; 38: 6850-66.
45. Yu DD, Wu Y, Shen HY, Lv MM, Chen WX, Zhang XH, et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci. 2015; 106: 959-64.
46. Yang W, Gu J, Wang X, Wang Y, Peng M, Zhou D, et al. Inhibition of circular RNA CDR1as increases chemosensitivity of 5-FU-resistant BC cells through up-regulating miR-7. J Cell Mol Med. 2019; 23: 3166-77.
47. Zhang H, Li Y, Zhang X, Huang G. Circ-RN1711 contributes to paclitaxel resistance in breast cancer by elevating EZF3 expression via miR-140-5p. Thorac Cancer. 2020; 11: 1891-903.
48. Yang W, Gong P, Yang Y, Yang C, Yang B, Ren L. Circ-ABCB10 contributes to paclitaxel resistance in breast cancer through let-7a-5p/DUSP7 axis. Cancer Manag Res. 2020; 12: 2327-37.
49. Guo J, Chen M, Ai G, Mao W, Li H, Zhou J. Hsa_circ_0023404 enhances cervical cancer metastasis and chemoresistance through VEGFA and autophagy signaling by sponging miR-5047. Biomed Pharmacother. 2019; 115: 108957.
50. Chen M, Ai G, Zhou J, Mao W, Li H, Guo J. circMTO1 promotes tumorigenesis and chemoresistance of cervical cancer via regulating miR-6893. Biomed Pharmacother. 2019; 117: 109064.
51. Xiong W, Ai YQ, Li YF, Ye Q, Chen ZT, Qin JY, et al. Microarray analysis of circular RNA expression profile associated with 5-fluouracil-based chemoradiation resistance in colorectal cancer cells. Biomed Res Int. 2017; 2017: 8421614.
52. Chen H, Pei L, Xie P, Guo G. Circ-PRKDC contributes to 5-fluouracil resistance of colorectal cancer cells by regulating miR-375/FOXM1 axis and Wnt/β-catenin pathway. Onco Targets Ther. 2020; 13: 5939-53.
53. Lin Y, Yu Y, Lin H, Hsiao K. Oxaliplatin-induced DHX9 phosphorylation promotes oncogenic circular RNA CCDC66 expression and development of chemoresistance. Cancers. 2020; 12(3): 697.
54. Yao W, Guo P, Mu Q, Wang Y. Exosome-derived circ-PVT1 contributes to cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p/YAP1 axis in gastric cancer cells [published online ahead of print, 2020 Aug 14]. Cancer Biother Radiopharm. 2020; 10.1089/cbr.2020.3578.
55. Huang XX, Zhang Q, Hu H, Jin Y, Zeng AL, Xia YR, et al. A novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR-182-5p [published online ahead of print, 2020 Jan 2]. J Cell Biochem. 2020; 10.1002/jcb.29641.
56. Sun H, Tang W, Rong D, Jin H, Fu K, Zhang W, et al. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomark. 2018; 21: 299-306.
Zhou Y, Zheng X, Xu B, Chen L, Wang Q, Deng H, et al. Circular RNA hsa_circ_0011292 enhances cisplatin chemoresistance in non-small cell lung cancer by sponging miR-498. Cell Death Discov. 2020; 5: 121.

Huang MS, Yuan FQ, Gao Y, Liu JY, Chen YX, Wang CJ, et al. Circular RNA hsa_circ_0007385 serves as a competing endogenous RNA for miR-379-5p/TRIM65 axis [published online ahead of print, 2020 Aug 21]. Cancer Biother Radiopharm. 2020; 10.1089/cbr.2020.3575.

Chen H, Liu S, Li M, Huang P, Li X. Circular RNA hsa_circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt/β-catenin pathway in hepatocellular carcinoma. Onco Targets Ther. 2019; 12: 9539-49.

Luo Y, Fu Y, Huang R, Gao M, Liu F, Gui R, et al. Circular RNA hsa_circ_0150515 sensitizes hepatocellular carcinoma cells to cisplatin by sponging miR-103 and promotes oxidized-nitro domain-containing protein 1 expression. Cell Death Discov. 2019; 5: 121.

Kong R. Circular RNA hsa_circ_0085131 is involved in cisplatin-resistance of non-small-cell lung cancer cells by regulating autophagy. Cell Biol Int. 2020; 44: 1945-56.

Yin H, Cui X. Knockdown of circHIPK3 facilitates temozolomide resistance in glioma by regulating miR-21 and miR-498. Cell Death Discov. 2020; 5: 121.

Li X, Liu Y, Zhang X, Shen J, Xu R, Liu Y, et al. Circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via miR-125a-5p/KIF2A-mediated PI3K/AKT pathway [published online ahead of print, 2020 Jun 27]. Cancer Biother Radiopharm. 2020; 10.1089/cbr.2020.3575.

Yu W, Peng W, Sha H, Li J. Hsa_circ_0003998 promotes cisplatin resistance via modulation of miR-326 in lung adenocarcinoma cells. Oncol Res. 2019; 27: 623-8.

Ma J, Qi G, Li L. A novel serum exosomes-based biomarker hsa_circ_0002130 facilitates osimertinib-resistance in non-small cell lung cancer by sponging miR-498. Onco Targets Ther. 2020; 13: 5293-307.

Zhu KP, Zhang CL, Ma XL, Hu JP, Cai T, Zhang L. Analyzing the interactions of miRNAs and ncRNAs to predict competing endogenous RNA networks in osteosarcoma chemo-resistance. Mol Ther. 2019; 27: 518-30.

Kun-Peng Z, Xiao-Long M, Lei Z, Chun-Lin Z, Jian-Ping H, Tai-Cheng Z. Screening circular RNA related to chemotherapeutic resistance in osteosarcoma by RNA sequencing. Epigenomics. 2018; 10: 1327-46.

Wang et al. Circular RNA and chemoresistance in cancer
84. Pan Y, Lou J, Wang H, An N, Chen H, Zhang Q, et al. CircBA9.3 supports the survival of leukemic cells by up-regulating c-ABL1 or BCR-ABL1 protein levels. Blood Cells Mol Dis. 2018; 73: 38-44.

85. Shang J, Chen WM, Liu S, Wang ZH, Wei TN, Chen ZZ, et al. CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy. Leuk Res. 2019; 85: 106198.

86. Nobili S, Lapucci A, Landini I, Coronnello M, Rovioi G, Mini E. Role of ATP-binding cassette transporters in cancer initiation and progression. Semin Cancer Biol. 2020; 60: 72-95.

87. Vlaming M, Mohrmann K, Wagenaar E, de Waart D, Elferink R, Loo T, Clarke D. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem. 2002; 277: 44332-8.

88. Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020; 14(3): 539-555.

89. Kun-Peng Z, Xiao-Long M, Chun-Lin Z. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1. Int J Biol Sci. 2018; 14: 321-30.

90. Zheng F, Xu R. CircPVT1 contributes to chemotherapeutic resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacotherapy. 2020; 124: 109828.

91. Gao F, Han J, Wang Y, Jia L, Luo W, Zeng Y. Circ_0109291 promotes the cisplatin resistance of oral squamous cell carcinoma by sponging miR-188-3p to increase ABCB1 expression [published online ahead of print, 2020 Aug 4]. Cancer Biother Radiopharm. 2020; 10.1089/cbr.2020.3928.

92. Hu X, Ma J, Zhang M, Cui J, Yang H. Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis. Cancer Biomark. 2020; 29(4): 527-534.

93. Xu QY, Xie MJ, Huang J, Wang ZW. Effect of circ MTHFD2 on resistance to paclitaxel in gastric cancer through regulating expression of miR-124. Eur Rev Med Pharmacol Sci. 2019; 23: 10290-9.

94. Hua L, Huang L, Zhang X, Feng H, Shen B. Knockdown of circular RNA CEP128 suppresses proliferation and improves cytotoxic efficacy of temozolomide in glioma cells by regulating miR-145-5p. Neuroreport. 2019; 30: 1231-8.

95. Gao M, Li C, Xiao H, Dong H, Jiang S, Fu Y, et al. hsa_circ_0007841: a novel potential biomarker and drug resistance for multiple myeloma. Front Oncol. 2019; 9: 1261.

96. Cecchaldi R, Rondinelli B, D’Andrea A. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016; 26: 52-64.

97. Blangy A, Lane H, d’Herin P, Harper M, Kress M, Nigg E. Phosphorylation by p34cd2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995; 83: 1159-69.

98. Savin K, LeGuellec K, Philippe M, Mitchison T. Mitotic spindle organization by a plus-end-directed microtubule motor. Nature. 1992; 359: 540-3.

99. DeBonis S, Simorre J, Crevel I, Lebeau L, Skoufias D, Blangy A, et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry. 2003; 42: 338-49.

100. Liu Y, Dong Y, Zhao L, Su L, Luo J. Circular RNA-MTO1 suppresses breast cancer cell viability and reverses monastrol resistance through regulating the TRAF4/Eg5 axis. Int J Oncol. 2018; 53: 1752-62.

101. Dilruba S, Kalaya G. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016; 77: 1103-24.

102. Li Q, Yu J, Mu C, Yunnbam M, Slavsky D, Cross C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000; 20: 645-52.

103. Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019; 18: 71.

104. Zhang Z, Yu X, Zhou B, Zhang J, Chang J. Circular RNA circ_0026359 enhances cisplatin resistance in gastric cancer via targeting miR-1200/POLD4 pathway. Biomed Res Int. 2020; 2020: 5103722.

105. Huang Q, Zeng Y, Zhang H, Lv L, Yang D, Lin H. 4-Nitroquinoline-1-oxide effects human lung adenocarcinoma A549 cells by regulating the expression of POLD4. Biomed Rep. 2016; 4: 345-8.

106. Pang J, Ye L, Zhao D, Zhao D, Chen Q. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer. Cell Biol Int. 2020; 44(12): 2416-2426.

107. Hui L, Chen Y. Tumor microenvironment: sanctuary of the devil. Cancer Lett. 2015; 368: 7-13.

108. Hu K, Liu X, Li Y, Li Q, Xu Y, Zeng W, et al. Exosomes mediated transfer of circ_UBE2D2 enhances the resistance of breast cancer to tamoxifen by binding to MiR-200a-3p. Med Sci Monit. 2020; 26: e922253.

109. Liu YY, Zhang LY, Du WZ. Circular RNA circ-PVT1 contributes to paclitaxel resistance of gastric cancer cells through the regulation of ZEB1 expression by sponging miR-124-3p. Biosci Rep. 2019; 39: BSR20193045.

110. Huang XY, Zhang PF, Wei CY, Peng R, Lu JC, Gao C, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020; 19: 92.

111. Zhang PF, Pei X, Li KS, Jin LN, Wang F, Wu J, et al. Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Oncol. 2019; 13: 2416-2426.

112. Joseph NA, Chiou SH, Lung Z, Yang CL, Lin TY, Chang HW, et al. The role of HGF-MET pathway and CCDC66 cirRNA expression in EGFR resistance and epithelial-to-mesenchymal transition of lung adenocarcinoma cells. J Hematol Oncol. 2018; 11: 74.

113. Chou M, Hu F, Yu C, Yu C. Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells. Oral Oncol. 2015; 51: 31-9.
115. Srivastava AK, Banerjee A, Cui T, Han C, Cai S, Liu L, et al. Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer. Cancer Res. 2019; 79: 2314-26.

116. Atkins RJ, Styli SS, Kurganov N, Mangiola S, Nowell CJ, Ware TM, et al. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Exp Cell Res. 2019; 374: 355-64.

117. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 2008; 8: 545-54.

118. Dhawan A, Madani Tonekaboni SA, Taube JH, Hu S, Sphyris N, Mani SA, et al. Mathematical modelling of phenotypic plasticity and conversion to a stem-cell state under hypoxia. Sci Rep. 2016; 6: 18074.

119. Su Y, Wang W, Jiang N, Shi J, Chen L, Zhong G, et al. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance. Int J Biol Sci. 2019; 15: 441-52.

120. Jian X, He H, Zhu J, Zhang Q, Zheng Z, Liang X, et al. Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340. Mol Cancer. 2020; 19: 20.

121. Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2020; 39: 149.

122. Rachner T, Coleman R, Hadji P, Hofbauer L. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol. 2018; 6: 901-10.

123. Murphy C, Dickler M. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016; 23: R337-52.

124. Shagufta, Ahmad I. Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018; 143: 515-31.

125. Huang H, Tindall DJ. The role of the androgen receptor in prostate cancer. Crit Rev Eukaryot Gene Expr. 2002; 12: 193-207.

126. Fujita K, Nonomura N. Role of androgen receptor in prostate cancer: a review. World J Mens Health. 2019; 37: 288-95.

127. Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, et al. circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther 2019; 27: 1638-52.

128. Liang Y, Song X, Li Y, Ma T, Su P, Guo R, et al. Targeting the circBMPR2/miR-553/USP4 axis as a potent therapeutic approach for breast cancer. Mol Ther Nucleic Acids. 2019; 17: 347-61.

129. Greene J, Baird AM, Casey O, Brady L, Blackshields G, Lim M, et al. Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. Sci Rep. 2019; 9: 10739.

130. Wu G, Sun Y, Xiang Z, Wang K, Liu B, Xiao G, et al. Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression. Cell Death Dis. 2019; 10: 37.

131. Xiang Z, Xu C, Wu G, Liu B, Wu D. CircRNA-UCK2 Increased TET1 inhibits proliferation and invasion of prostate cancer cells via sponge MiRNA-767-5p. Open Med (Wars). 2019; 14: 833-42.

132. Chen W, Wang P, Lu Y, Jin T, Lei X, Liu M, et al. Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation. Theranostics. 2019; 9: 5739-54.

133. Seidl C, Panzitt K, Bertsch A, Bricc L, Schein S, Mack M, et al. MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2. Cancer Lett. 2020; 469: 266-76.

134. Rupaimoole R, Slack F. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16: 203-22.

Cite this article as: Wang J, Zhang Y, Liu L, Yang T, Song J. Circular RNAs: new biomarkers of chemoresistance in cancer. Cancer Biol Med. 2021; 18: 421-436. doi: 10.20892/j.issn.2095-3941.2020.0312